You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameRopivacaine
Accession NumberDB00296  (APRD00492)
TypeSmall Molecule
GroupsApproved
DescriptionRopivacaine is a local anaesthetic drug belonging to the amino amide group. The name ropivacaine refers to both the racemate and the marketed S-enantiomer. Ropivacaine hydrochloride is commonly marketed by AstraZeneca under the trade name Naropin. [Wikipedia]
Structure
Thumb
Synonyms
(S)-(−)-1-propyl-2',6'-pipecoloxylidide
(S)-ropivacaine
L-N-n-propylpipecolic acid-2,6-xylidide
Ropivacaina
Ropivacaine
Ropivacainum
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
NaropinInjection, solution5 mg/mLEpidural; Infiltration; PerineuralGeneral Injectables & Vaccines, Inc2014-03-11Not applicableUs
NaropinInjection, solution10 mg/mLEpiduralFresenius Kabi USA, LLC2009-08-04Not applicableUs
NaropinInjection, solution2 mg/mLEpidural; InfiltrationFresenius Kabi USA, LLC2009-08-04Not applicableUs
NaropinInjection, solution5 mg/mLEpidural; Infiltration; PerineuralAPP Pharmaceuticals, LLC2009-08-04Not applicableUs
NaropinInjection, solution7.5 mg/mLEpidural; PerineuralFresenius Kabi USA, LLC2011-05-31Not applicableUs
Naropin Inj 10mg/mlSolution10 mgEpiduralAstrazeneca Canada Inc1997-04-30Not applicableCanada
Naropin Inj 2mg/mlSolution2 mgEpidural; InfiltrationAstrazeneca Canada Inc1997-04-30Not applicableCanada
Naropin Inj 5mg/mlSolution5 mgEpiduralAstrazeneca Canada Inc1997-04-30Not applicableCanada
Naropin Inj 7.5mg/mlLiquid7.5 mgParenteralAstrazeneca Canada Inc1997-04-302003-11-18Canada
Ropivacaine Hydrochloride InjectionSolution2 mgEpidural; InfiltrationTeva Canada LimitedNot applicableNot applicableCanada
Ropivacaine Hydrochloride Injection USPSolution5 mgEpidural; InfiltrationHospira Healthcare Corporation2010-12-14Not applicableCanada
Ropivacaine Hydrochloride Injection USPSolution10 mgEpidural; InfiltrationHospira Healthcare Corporation2010-12-14Not applicableCanada
Ropivacaine Hydrochloride Injection, USPSolution7.5 mgEpiduralFresenius Kabi Canada LtdNot applicableNot applicableCanada
Ropivacaine Hydrochloride Injection, USPSolution2 mgInfiltrationHospira Healthcare CorporationNot applicableNot applicableCanada
Ropivacaine Hydrochloride Injection, USPSolution10 mgEpiduralFresenius Kabi Canada LtdNot applicableNot applicableCanada
Ropivacaine Hydrochloride Injection, USPSolution2 mgEpidural; InfiltrationFresenius Kabi Canada LtdNot applicableNot applicableCanada
Ropivacaine Hydrochloride Injection, USPSolution5 mgEpidural; InfiltrationFresenius Kabi Canada LtdNot applicableNot applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Ropivacaine HydrochlorideInjection, solution2 mg/mLEpidural; Infiltration; PerineuralHospira, Inc.2014-09-23Not applicableUs
Ropivacaine HydrochlorideInjection, solution7.5 mg/mLEpidural; PerineuralAuro Medics Pharma Llc2016-09-15Not applicableUs
Ropivacaine HydrochlorideInjection, solution5 mg/mLParenteralSandoz Inc2014-07-24Not applicableUs
Ropivacaine HydrochlorideInjection, solution2 mg/mLEpidural; Infiltration; PerineuralAuro Medics Pharma Llc2016-09-15Not applicableUs
Ropivacaine HydrochlorideInjection, solution7.5 mg/mLEpidural; PerineuralSagent Pharmaceuticals2014-09-23Not applicableUs
Ropivacaine HydrochlorideInjection, solution5 mg/mLEpidural; Infiltration; PerineuralHospira, Inc.2014-09-23Not applicableUs
Ropivacaine HydrochlorideInjection, solution10 mg/mLEpiduralAuro Medics Pharma Llc2016-09-15Not applicableUs
Ropivacaine HydrochlorideInjection, solution10 mg/mLParenteralSandoz Inc2014-07-24Not applicableUs
Ropivacaine HydrochlorideInjection, solution2 mg/mLEpidural; Infiltration; PerineuralAuro Medics Pharma Llc2016-09-15Not applicableUs
Ropivacaine HydrochlorideInjection, solution2 mg/mLEpidural; Infiltration; PerineuralSagent Pharmaceuticals2014-09-23Not applicableUs
Ropivacaine HydrochlorideInjection, solution7.5 mg/mLEpidural; PerineuralHospira, Inc.2014-09-23Not applicableUs
Ropivacaine HydrochlorideInjection, solution10 mg/mLEpiduralAuro Medics Pharma Llc2016-09-15Not applicableUs
Ropivacaine HydrochlorideInjection, solution5 mg/mLEpidural; Infiltration; PerineuralSagent Pharmaceuticals2014-09-23Not applicableUs
Ropivacaine HydrochlorideInjection, solution5 mg/mLEpidural; Infiltration; PerineuralAuro Medics Pharma Llc2016-09-15Not applicableUs
Ropivacaine HydrochlorideInjection, solution5 mg/mLEpidural; Infiltration; PerineuralAkorn, Inc.2016-04-11Not applicableUs
Ropivacaine HydrochlorideInjection, solution10 mg/mLEpiduralHospira, Inc.2014-09-23Not applicableUs
Ropivacaine HydrochlorideInjection, solution10 mg/mLEpiduralSagent Pharmaceuticals2014-09-23Not applicableUs
Ropivacaine HydrochlorideInjection, solution5 mg/mLEpidural; Infiltration; PerineuralAuro Medics Pharma Llc2016-09-15Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Ropivacaine hydrochloride
ThumbNot applicableDBSALT000902
Ropivacaine hydrochloride monohydrate
ThumbNot applicableDBSALT001585
Categories
UNII7IO5LYA57N
CAS number84057-95-4
WeightAverage: 274.4011
Monoisotopic: 274.204513464
Chemical FormulaC17H26N2O
InChI KeyZKMNUMMKYBVTFN-GGYSOQFKNA-N
InChI
InChI=1/C17H26N2O/c1-4-11-19-12-6-5-10-15(19)17(20)18-16-13(2)8-7-9-14(16)3/h7-9,15H,4-6,10-12H2,1-3H3,(H,18,20)/t15-/s2
IUPAC Name
(2S)-N-(2,6-dimethylphenyl)-1-propylpiperidine-2-carboxamide
SMILES
CCCN1CCCC[[email protected]]1C(=O)NC1=C(C)C=CC=C1C
Pharmacology
IndicationUsed in obstetric anesthesia and regional anesthesia for surgery.
Structured Indications
PharmacodynamicsRopivacaine, a local anesthetic agent, is indicated for the production of local or regional anesthesia or analgesia for surgery, for oral surgery procedures, for diagnostic and therapeutic procedures, and for obstetrical procedures.
Mechanism of actionLocal anesthetics such as Ropivacaine block the generation and the conduction of nerve impulses, presumably by increasing the threshold for electrical excitation in the nerve, by slowing the propagation of the nerve impulse, and by reducing the rate of rise of the action potential. Specifically, they block the sodium-channel and decrease chances of depolarization and consequent action potentials. In general, the progression of anesthesia is related to the diameter, myelination and conduction velocity of affected nerve fibers.
TargetKindPharmacological actionActionsOrganismUniProt ID
Sodium channel protein type 10 subunit alphaProteinyes
inhibitor
HumanQ9Y5Y9 details
Related Articles
AbsorptionBioavailability is 87%–98% following epidural administration.
Volume of distributionNot Available
Protein binding94%, mainly to a1-acid glycoprotein
Metabolism

Hepatic

SubstrateEnzymesProduct
Ropivacaine
3-hydroxyropivacaineDetails
Route of eliminationRopivacaine is extensively metabolized in the liver, predominantly by aromatic hydroxylation mediated by cytochrome P4501A to 3-hydroxy ropivacaine. After a single IV dose approximately 37% of the total dose is excreted in the urine as both free and conjugated 3-hydroxy ropivacaine. In total, 86% of the ropivacaine dose is excreted in the urine after intravenous administration of which only 1% relates to unchanged drug.
Half lifeApproximately 4.2 hours.
Clearance
  • 387 +/- 107 mL/min
  • unbound plasma clearance=7.2 +/- 1.6 L/min
ToxicitySystemic exposure to excessive quantities of ropivacaine mainly result in central nervous system (CNS) and cardiovascular effects – CNS effects usually occur at lower blood plasma concentrations and additional cardiovascular effects present at higher concentrations, though cardiovascular collapse may also occur with low concentrations. CNS effects may include CNS excitation (nervousness, tingling around the mouth, tinnitus, tremor, dizziness, blurred vision, seizures) followed by depression (drowsiness, loss of consciousness, respiratory depression and apnea). Cardiovascular effects include hypotension, bradycardia, arrhythmias, and/or cardiac arrest – some of which may be due to hypoxemia secondary to respiratory depression.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Ropivacaine Action PathwayDrug actionSMP00404
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,1,1,2 TetrafluoroethaneThe risk or severity of adverse effects can be increased when Ropivacaine is combined with 1,1,1,2 Tetrafluoroethane.Investigational
7-NitroindazoleThe risk or severity of adverse effects can be increased when Ropivacaine is combined with 7-Nitroindazole.Experimental
AbirateroneThe serum concentration of Ropivacaine can be increased when it is combined with Abiraterone.Approved
AcebutololThe risk or severity of adverse effects can be increased when Acebutolol is combined with Ropivacaine.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Aceprometazine.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Acetazolamide.Approved, Vet Approved
adipiplonThe risk or severity of adverse effects can be increased when Ropivacaine is combined with adipiplon.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Agomelatine.Approved, Investigational
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Ropivacaine.Approved
AlfaxaloneThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Alfentanil.Approved, Illicit
AliskirenThe risk or severity of adverse effects can be increased when Aliskiren is combined with Ropivacaine.Approved, Investigational
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Alphacetylmethadol.Experimental, Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Alprazolam.Approved, Illicit, Investigational
AmifostineThe risk or severity of adverse effects can be increased when Amifostine is combined with Ropivacaine.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Ropivacaine.Approved
AmiodaroneThe metabolism of Ropivacaine can be decreased when combined with Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Amisulpride.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Amitriptyline.Approved
AmlodipineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Ropivacaine.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Amobarbital.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Amperozide.Experimental
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Ropivacaine.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Amyl Nitrite is combined with Ropivacaine.Approved
ApomorphineThe risk or severity of adverse effects can be increased when Apomorphine is combined with Ropivacaine.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Apraclonidine is combined with Ropivacaine.Approved
AprepitantThe serum concentration of Ropivacaine can be increased when it is combined with Aprepitant.Approved, Investigational
AripiprazoleAripiprazole may increase the hypotensive activities of Ropivacaine.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Arotinolol is combined with Ropivacaine.Approved
Arsenic trioxideThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Ropivacaine.Approved, Investigational
ArtemetherThe metabolism of Ropivacaine can be decreased when combined with Artemether.Approved
ArticaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Articaine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Asenapine.Approved
AtazanavirThe metabolism of Ropivacaine can be decreased when combined with Atazanavir.Approved, Investigational
AtenololThe risk or severity of adverse effects can be increased when Atenolol is combined with Ropivacaine.Approved
AtomoxetineThe metabolism of Ropivacaine can be decreased when combined with Atomoxetine.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Azaperone.Vet Approved
AzelastineRopivacaine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzelastineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Azelastine.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Ropivacaine.Approved
AzithromycinThe metabolism of Ropivacaine can be decreased when combined with Azithromycin.Approved
BaclofenThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Baclofen.Approved
BarbexacloneBarbexaclone may increase the hypotensive activities of Ropivacaine.Experimental
BarbitalThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Barbital.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Barnidipine is combined with Ropivacaine.Approved
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Ropivacaine.Approved, Investigational
BendroflumethiazideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Ropivacaine.Approved
BenperidolThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Benperidol.Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Benzocaine.Approved
Benzyl alcoholThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Benzyl alcohol.Approved
BepridilThe risk or severity of adverse effects can be increased when Bepridil is combined with Ropivacaine.Approved, Withdrawn
BetaxololThe metabolism of Ropivacaine can be decreased when combined with Betaxolol.Approved
BexaroteneThe serum concentration of Ropivacaine can be decreased when it is combined with Bexarotene.Approved, Investigational
BisoprololThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Ropivacaine.Approved
BoceprevirThe metabolism of Ropivacaine can be decreased when combined with Boceprevir.Approved
BortezomibThe metabolism of Ropivacaine can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Ropivacaine can be decreased when it is combined with Bosentan.Approved, Investigational
BretyliumThe risk or severity of adverse effects can be increased when Bretylium is combined with Ropivacaine.Approved
BrexpiprazoleThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Brexpiprazole.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Brimonidine.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Ropivacaine.Approved
BromazepamThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Bromazepam.Approved, Illicit
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Ropivacaine.Approved, Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Brotizolam.Approved, Withdrawn
BumetanideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Ropivacaine.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Bupivacaine.Approved, Investigational
BuprenorphineRopivacaine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe metabolism of Ropivacaine can be decreased when combined with Bupropion.Approved
BuspironeThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Buspirone.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Ropivacaine.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Butalbital.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Butamben.Approved
ButethalThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Butethal.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Butorphanol.Approved, Illicit, Vet Approved
CaffeineThe metabolism of Ropivacaine can be decreased when combined with Caffeine.Approved
CanagliflozinThe risk or severity of adverse effects can be increased when Canagliflozin is combined with Ropivacaine.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Ropivacaine.Approved
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Ropivacaine.Approved
CarbamazepineThe metabolism of Ropivacaine can be increased when combined with Carbamazepine.Approved, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Carbetocin is combined with Ropivacaine.Approved
CarbinoxamineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Carfentanil.Illicit, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Carisoprodol.Approved
CarteololThe risk or severity of adverse effects can be increased when Carteolol is combined with Ropivacaine.Approved
CarvedilolThe risk or severity of adverse effects can be increased when Carvedilol is combined with Ropivacaine.Approved, Investigational
CelecoxibThe metabolism of Ropivacaine can be decreased when combined with Celecoxib.Approved, Investigational
CeritinibThe serum concentration of Ropivacaine can be increased when it is combined with Ceritinib.Approved
CetirizineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Cetirizine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Chloral hydrate.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Chlordiazepoxide.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Chlormezanone.Approved, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Chloroprocaine.Approved
ChloroquineThe metabolism of Ropivacaine can be decreased when combined with Chloroquine.Approved, Vet Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Ropivacaine.Approved, Vet Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Chlorphenamine.Approved
ChlorpromazineThe metabolism of Ropivacaine can be decreased when combined with Chlorpromazine.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Chlorprothixene.Approved, Withdrawn
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Ropivacaine.Approved
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Chlorzoxazone.Approved
CholecalciferolThe metabolism of Ropivacaine can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Ropivacaine.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Ropivacaine.Approved
CimetidineThe metabolism of Ropivacaine can be decreased when combined with Cimetidine.Approved
CinacalcetThe metabolism of Ropivacaine can be decreased when combined with Cinacalcet.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Cinchocaine.Approved, Vet Approved
CiprofloxacinThe serum concentration of Ropivacaine can be increased when it is combined with Ciprofloxacin.Approved, Investigational
CitalopramThe metabolism of Ropivacaine can be decreased when combined with Citalopram.Approved
ClarithromycinThe metabolism of Ropivacaine can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Ropivacaine can be decreased when combined with Clemastine.Approved
ClevidipineThe risk or severity of adverse effects can be increased when Clevidipine is combined with Ropivacaine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Clidinium.Approved
ClobazamThe metabolism of Ropivacaine can be decreased when combined with Clobazam.Approved, Illicit
ClofarabineThe risk or severity of adverse effects can be increased when Clofarabine is combined with Ropivacaine.Approved, Investigational
clomethiazoleThe risk or severity of adverse effects can be increased when Ropivacaine is combined with clomethiazole.Investigational
ClomipramineThe metabolism of Ropivacaine can be decreased when combined with Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Clonidine.Approved
ClopidogrelThe metabolism of Ropivacaine can be decreased when combined with Clopidogrel.Approved, Nutraceutical
ClorazepateThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Clorazepate.Approved, Illicit
ClotrimazoleThe metabolism of Ropivacaine can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe metabolism of Ropivacaine can be decreased when combined with Clozapine.Approved
CobicistatThe serum concentration of Ropivacaine can be increased when it is combined with Cobicistat.Approved
CocaineThe metabolism of Ropivacaine can be decreased when combined with Cocaine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Codeine.Approved, Illicit
ConivaptanThe serum concentration of Ropivacaine can be increased when it is combined with Conivaptan.Approved, Investigational
CrizotinibThe metabolism of Ropivacaine can be decreased when combined with Crizotinib.Approved
CyclizineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Cyclobenzaprine.Approved
CyclosporineThe metabolism of Ropivacaine can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Cyproheptadine.Approved
Cyproterone acetateThe serum concentration of Ropivacaine can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
DabrafenibThe serum concentration of Ropivacaine can be decreased when it is combined with Dabrafenib.Approved
DantroleneThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Dantrolene.Approved
DapagliflozinThe risk or severity of adverse effects can be increased when Dapagliflozin is combined with Ropivacaine.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Dapiprazole.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Dapoxetine.Investigational
DarifenacinThe metabolism of Ropivacaine can be decreased when combined with Darifenacin.Approved, Investigational
DarunavirThe serum concentration of Ropivacaine can be increased when it is combined with Darunavir.Approved
DasatinibThe serum concentration of Ropivacaine can be increased when it is combined with Dasatinib.Approved, Investigational
DeferasiroxThe serum concentration of Ropivacaine can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Ropivacaine can be decreased when combined with Delavirdine.Approved
deramciclaneThe risk or severity of adverse effects can be increased when Ropivacaine is combined with deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Desflurane.Approved
DesipramineThe metabolism of Ropivacaine can be decreased when combined with Desipramine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Desloratadine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Desvenlafaxine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Detomidine.Vet Approved
DexamethasoneThe serum concentration of Ropivacaine can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Dexbrompheniramine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Dexmedetomidine.Approved, Vet Approved
DextromoramideThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Dextropropoxyphene.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Dezocine.Approved
DiazepamThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Diazepam.Approved, Illicit, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Ropivacaine.Approved
DifenoxinThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Dihydrocodeine.Approved, Illicit
DihydroergotamineThe metabolism of Ropivacaine can be decreased when combined with Dihydroergotamine.Approved
DihydroetorphineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Dihydromorphine.Experimental, Illicit
DiltiazemThe metabolism of Ropivacaine can be decreased when combined with Diltiazem.Approved
DimenhydrinateThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Dimenhydrinate.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Dinutuximab is combined with Ropivacaine.Approved
DiphenhydramineThe metabolism of Ropivacaine can be decreased when combined with Diphenhydramine.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Diphenoxylate.Approved, Illicit
DipyridamoleThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Ropivacaine.Approved
DoramectinThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Doramectin.Vet Approved
DoxazosinThe risk or severity of adverse effects can be increased when Doxazosin is combined with Ropivacaine.Approved
DoxepinThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Doxepin.Approved
DoxorubicinThe metabolism of Ropivacaine can be decreased when combined with Doxorubicin.Approved, Investigational
DoxycyclineThe metabolism of Ropivacaine can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Ropivacaine.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Ropivacaine is combined with DPDPE.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Ropivacaine.Approved, Illicit
DronedaroneThe metabolism of Ropivacaine can be decreased when combined with Dronedarone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Ropivacaine.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Drotebanol.Experimental, Illicit
DuloxetineRopivacaine may increase the orthostatic hypotensive activities of Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Dyclonine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Ecgonine.Experimental, Illicit
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Ropivacaine is combined with ECGONINE METHYL ESTER.Experimental
EcopipamThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Ecopipam.Investigational
EfavirenzThe serum concentration of Ropivacaine can be decreased when it is combined with Efavirenz.Approved, Investigational
EfonidipineThe risk or severity of adverse effects can be increased when Efonidipine is combined with Ropivacaine.Approved
EliglustatThe metabolism of Ropivacaine can be decreased when combined with Eliglustat.Approved
EmpagliflozinThe risk or severity of adverse effects can be increased when Empagliflozin is combined with Ropivacaine.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Ropivacaine.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Ropivacaine.Approved
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Ropivacaine.Approved, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Entacapone.Approved, Investigational
EnzalutamideThe serum concentration of Ropivacaine can be decreased when it is combined with Enzalutamide.Approved
EplerenoneThe risk or severity of adverse effects can be increased when Eplerenone is combined with Ropivacaine.Approved
EpoprostenolThe risk or severity of adverse effects can be increased when Epoprostenol is combined with Ropivacaine.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Ropivacaine.Approved
ErythromycinThe metabolism of Ropivacaine can be decreased when combined with Erythromycin.Approved, Vet Approved
EscitalopramThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Escitalopram.Approved, Investigational
Eslicarbazepine acetateThe serum concentration of Ropivacaine can be decreased when it is combined with Eslicarbazepine acetate.Approved
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Ropivacaine.Approved
EstazolamThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Estazolam.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Eszopiclone.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Ropivacaine.Approved
EthanolRopivacaine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Ropivacaine.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Ethotoin.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Ethyl carbamate.Withdrawn
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Ethylmorphine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Etifoxine.Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Ropivacaine.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Etoperidone.Approved
EtorphineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Etorphine.Illicit, Vet Approved
EtravirineThe serum concentration of Ropivacaine can be decreased when it is combined with Etravirine.Approved
EzogabineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Ezogabine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Felbamate.Approved
FelodipineThe risk or severity of adverse effects can be increased when Felodipine is combined with Ropivacaine.Approved, Investigational
FencamfamineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Fencamfamine.Approved, Illicit, Withdrawn
FenoldopamThe risk or severity of adverse effects can be increased when Fenoldopam is combined with Ropivacaine.Approved
FentanylThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Fexofenadine.Approved
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Ropivacaine.Approved
FlibanserinThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Flibanserin.Approved
FluconazoleThe metabolism of Ropivacaine can be decreased when combined with Fluconazole.Approved
FludiazepamThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Fludiazepam.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Flunitrazepam.Approved, Illicit
FluoxetineThe metabolism of Ropivacaine can be decreased when combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Flupentixol.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Fluphenazine.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Flurazepam.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Fluspirilene.Approved
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Fluticasone Propionate.Approved
FluvoxamineThe serum concentration of Ropivacaine can be increased when it is combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe metabolism of Ropivacaine can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Ropivacaine can be increased when it is combined with Fosaprepitant.Approved
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Ropivacaine.Approved
FosphenytoinThe metabolism of Ropivacaine can be increased when combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Fospropofol.Approved, Illicit
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Ropivacaine.Approved, Vet Approved
Fusidic AcidThe serum concentration of Ropivacaine can be increased when it is combined with Fusidic Acid.Approved
GabapentinThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Gabapentin.Approved, Investigational
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Ropivacaine is combined with gabapentin enacarbil.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Gamma Hydroxybutyric Acid.Approved, Illicit
GepironeThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Glutethimide.Approved, Illicit
GuanfacineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Halazepam.Approved, Illicit, Withdrawn
HaloperidolThe metabolism of Ropivacaine can be decreased when combined with Haloperidol.Approved
HalothaneThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Halothane.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Heroin.Approved, Illicit
HexobarbitalThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Hexobarbital.Approved
HyaluronidaseThe risk or severity of adverse effects can be increased when Hyaluronidase is combined with Ropivacaine.Approved, Investigational
HydralazineThe risk or severity of adverse effects can be increased when Hydralazine is combined with Ropivacaine.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Ropivacaine.Approved, Vet Approved
HydrocodoneRopivacaine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydroflumethiazideThe risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Ropivacaine.Approved
HydromorphoneThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Hydromorphone.Approved, Illicit
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Ropivacaine.Approved
IdelalisibThe serum concentration of Ropivacaine can be increased when it is combined with Idelalisib.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Iloperidone.Approved
IloprostThe risk or severity of adverse effects can be increased when Iloprost is combined with Ropivacaine.Approved, Investigational
ImatinibThe metabolism of Ropivacaine can be decreased when combined with Imatinib.Approved
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Ropivacaine.Investigational
ImipramineThe metabolism of Ropivacaine can be decreased when combined with Imipramine.Approved
IndalpineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Indalpine.Investigational, Withdrawn
IndapamideThe risk or severity of adverse effects can be increased when Indapamide is combined with Ropivacaine.Approved
IndinavirThe metabolism of Ropivacaine can be decreased when combined with Indinavir.Approved
IndoraminThe risk or severity of adverse effects can be increased when Indoramin is combined with Ropivacaine.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Ropivacaine.Approved, Investigational
IsavuconazoniumThe metabolism of Ropivacaine can be decreased when combined with Isavuconazonium.Approved, Investigational
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Ropivacaine.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Isoflurane.Approved, Vet Approved
IsoniazidThe metabolism of Ropivacaine can be decreased when combined with Isoniazid.Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Ropivacaine.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Ropivacaine.Approved
IsoxsuprineThe risk or severity of adverse effects can be increased when Isoxsuprine is combined with Ropivacaine.Approved, Withdrawn
IsradipineThe metabolism of Ropivacaine can be decreased when combined with Isradipine.Approved
ItraconazoleThe metabolism of Ropivacaine can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Ropivacaine can be increased when it is combined with Ivacaftor.Approved
KetamineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Ketamine.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Ketazolam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Ketobemidone.Approved
KetoconazoleThe metabolism of Ropivacaine can be decreased when combined with Ketoconazole.Approved, Investigational
LabetalolThe risk or severity of adverse effects can be increased when Labetalol is combined with Ropivacaine.Approved
LacidipineThe risk or severity of adverse effects can be increased when Lacidipine is combined with Ropivacaine.Approved
LamotrigineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Lamotrigine.Approved, Investigational
LercanidipineThe risk or severity of adverse effects can be increased when Lercanidipine is combined with Ropivacaine.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Levetiracetam.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Levobunolol is combined with Ropivacaine.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Levobupivacaine.Approved
LevocabastineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Levocetirizine.Approved
LevodopaRopivacaine may increase the orthostatic hypotensive activities of Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Levomethadyl Acetate.Approved
LevomilnacipranThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Levomilnacipran.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Levorphanol.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Levosimendan is combined with Ropivacaine.Approved, Investigational
LidocaineThe metabolism of Ropivacaine can be decreased when combined with Lidocaine.Approved, Vet Approved
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Ropivacaine.Approved, Investigational
LithiumThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Lithium.Approved
LofentanilThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Lofentanil.Illicit
LofexidineThe risk or severity of adverse effects can be increased when Lofexidine is combined with Ropivacaine.Approved, Investigational
LopinavirThe metabolism of Ropivacaine can be decreased when combined with Lopinavir.Approved
LoratadineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Loratadine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Ropivacaine.Approved
LorcaserinThe metabolism of Ropivacaine can be decreased when combined with Lorcaserin.Approved
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Ropivacaine.Approved
LovastatinThe metabolism of Ropivacaine can be decreased when combined with Lovastatin.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Loxapine.Approved
Lu AA21004The risk or severity of adverse effects can be increased when Ropivacaine is combined with Lu AA21004.Investigational
LuliconazoleThe serum concentration of Ropivacaine can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Ropivacaine can be decreased when it is combined with Lumacaftor.Approved
LumefantrineThe metabolism of Ropivacaine can be decreased when combined with Lumefantrine.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Lurasidone.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Ropivacaine.Approved, Vet Approved
MannitolThe risk or severity of adverse effects can be increased when Mannitol is combined with Ropivacaine.Approved, Investigational
MaprotilineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Maprotiline.Approved
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Ropivacaine.Approved
MeclizineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Meclizine.Approved
MedetomidineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Medetomidine.Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Melatonin.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Melperone.Approved
MepivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Mepivacaine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Meprobamate.Approved, Illicit
MesoridazineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Mesoridazine.Approved
MetaxaloneThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Metaxalone.Approved
MethadoneThe metabolism of Ropivacaine can be decreased when combined with Methadone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Methadyl Acetate.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Methaqualone.Illicit, Withdrawn
MethazolamideThe risk or severity of adverse effects can be increased when Methazolamide is combined with Ropivacaine.Approved
MethocarbamolThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Methohexital.Approved
MethotrimeprazineRopivacaine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Methoxyflurane.Approved, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Methsuximide.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Ropivacaine.Approved
MethyldopaThe risk or severity of adverse effects can be increased when Methyldopa is combined with Ropivacaine.Approved
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Methylphenobarbital.Approved
MetipranololThe risk or severity of adverse effects can be increased when Metipranolol is combined with Ropivacaine.Approved
MetolazoneThe risk or severity of adverse effects can be increased when Metolazone is combined with Ropivacaine.Approved
MetoprololThe metabolism of Ropivacaine can be decreased when combined with Metoprolol.Approved, Investigational
MetyrosineRopivacaine may increase the sedative activities of Metyrosine.Approved
MexiletineThe metabolism of Ropivacaine can be decreased when combined with Mexiletine.Approved
MidazolamThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Midazolam.Approved, Illicit
MifepristoneThe serum concentration of Ropivacaine can be increased when it is combined with Mifepristone.Approved, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Milnacipran.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Ropivacaine.Approved, Investigational
MinoxidilThe risk or severity of adverse effects can be increased when Minoxidil is combined with Ropivacaine.Approved
MirabegronThe metabolism of Ropivacaine can be decreased when combined with Mirabegron.Approved
MirtazapineRopivacaine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MitotaneThe serum concentration of Ropivacaine can be decreased when it is combined with Mitotane.Approved
ModafinilThe serum concentration of Ropivacaine can be decreased when it is combined with Modafinil.Approved, Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Ropivacaine.Approved
MolindoneThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Molindone.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Ropivacaine.Approved, Investigational
MoxonidineThe risk or severity of adverse effects can be increased when Moxonidine is combined with Ropivacaine.Approved
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Ropivacaine.Approved, Investigational
NadololThe risk or severity of adverse effects can be increased when Nadolol is combined with Ropivacaine.Approved
NafcillinThe serum concentration of Ropivacaine can be decreased when it is combined with Nafcillin.Approved
NalbuphineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Nalbuphine.Approved
NebivololThe risk or severity of adverse effects can be increased when Nebivolol is combined with Ropivacaine.Approved, Investigational
NefazodoneThe metabolism of Ropivacaine can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Ropivacaine can be decreased when combined with Nelfinavir.Approved
NesiritideThe risk or severity of adverse effects can be increased when Nesiritide is combined with Ropivacaine.Approved, Investigational
NetupitantThe serum concentration of Ropivacaine can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Ropivacaine can be increased when combined with Nevirapine.Approved
NicardipineThe metabolism of Ropivacaine can be decreased when combined with Nicardipine.Approved
NicorandilNicorandil may increase the hypotensive activities of Ropivacaine.Approved
NifedipineThe risk or severity of adverse effects can be increased when Nifedipine is combined with Ropivacaine.Approved
NilotinibThe metabolism of Ropivacaine can be decreased when combined with Nilotinib.Approved, Investigational
NilvadipineThe risk or severity of adverse effects can be increased when Nilvadipine is combined with Ropivacaine.Approved
NimodipineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Ropivacaine.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Ropivacaine.Approved
NitrazepamThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Nitrazepam.Approved
NitrendipineThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Ropivacaine.Approved
Nitric OxideThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Ropivacaine.Approved
NitroglycerinThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Ropivacaine.Approved, Investigational
NitroprussideThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Ropivacaine.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Nitrous oxide.Approved, Vet Approved
NormethadoneThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Nortriptyline.Approved
ObinutuzumabThe risk or severity of adverse effects can be increased when Obinutuzumab is combined with Ropivacaine.Approved
OlanzapineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Olanzapine.Approved, Investigational
OlaparibThe metabolism of Ropivacaine can be decreased when combined with Olaparib.Approved
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Ropivacaine.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Olopatadine.Approved
OndansetronThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Ondansetron.Approved
OpiumThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Opium.Approved, Illicit
OrphenadrineRopivacaine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Osanetant.Investigational
OsimertinibThe serum concentration of Ropivacaine can be increased when it is combined with Osimertinib.Approved
OxazepamThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Oxazepam.Approved
OxetacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Oxetacaine.Investigational
OxprenololThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Oxprenolol.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Oxybuprocaine.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Oxycodone.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Oxymorphone.Approved, Investigational, Vet Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Ropivacaine.Approved, Vet Approved
PalbociclibThe serum concentration of Ropivacaine can be increased when it is combined with Palbociclib.Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Paliperidone.Approved
PanobinostatThe serum concentration of Ropivacaine can be increased when it is combined with Panobinostat.Approved, Investigational
PapaverineThe risk or severity of adverse effects can be increased when Papaverine is combined with Ropivacaine.Approved
ParaldehydeRopivacaine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved
ParoxetineThe metabolism of Ropivacaine can be decreased when combined with Paroxetine.Approved, Investigational
Peginterferon alfa-2bThe serum concentration of Ropivacaine can be decreased when it is combined with Peginterferon alfa-2b.Approved
PenbutololThe risk or severity of adverse effects can be increased when Penbutolol is combined with Ropivacaine.Approved, Investigational
PentazocineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Pentazocine.Approved, Vet Approved
PentobarbitalThe metabolism of Ropivacaine can be increased when combined with Pentobarbital.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Ropivacaine.Approved
PerazineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Perazine.Investigational
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Ropivacaine.Approved
PerospironeThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Perphenazine.Approved
PethidineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Pethidine.Approved
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Ropivacaine.Approved
PhenobarbitalThe metabolism of Ropivacaine can be increased when combined with Phenobarbital.Approved
PhenoxybenzamineThe risk or severity of adverse effects can be increased when Phenoxybenzamine is combined with Ropivacaine.Approved
PhenoxyethanolThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Phenoxyethanol.Approved
PhentolamineThe risk or severity of adverse effects can be increased when Phentolamine is combined with Ropivacaine.Approved
PhenytoinThe metabolism of Ropivacaine can be increased when combined with Phenytoin.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Pimozide.Approved
PindololThe risk or severity of adverse effects can be increased when Pindolol is combined with Ropivacaine.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Pipamperone.Approved
PipotiazineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Pipotiazine.Approved
PiritramideThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Piritramide.Investigational
PizotifenThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Pizotifen.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Pomalidomide.Approved
PosaconazoleThe metabolism of Ropivacaine can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PramipexoleRopivacaine may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Pramocaine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Prazepam.Approved, Illicit
PrazosinThe risk or severity of adverse effects can be increased when Prazosin is combined with Ropivacaine.Approved
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Ropivacaine.Approved, Illicit, Investigational
PregnanoloneThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Pregnanolone.Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Prilocaine.Approved
PrimidoneThe metabolism of Ropivacaine can be increased when combined with Primidone.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Procaine.Approved, Investigational, Vet Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Prochlorperazine.Approved, Vet Approved
PromazineThe metabolism of Ropivacaine can be decreased when combined with Promazine.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Promethazine.Approved
ProparacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Proparacaine.Approved, Vet Approved
PropofolThe serum concentration of Ropivacaine can be increased when it is combined with Propofol.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Propoxycaine.Approved
PropranololThe risk or severity of adverse effects can be increased when Propranolol is combined with Ropivacaine.Approved, Investigational
ProtriptylineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Protriptyline.Approved
PSD502The risk or severity of adverse effects can be increased when Ropivacaine is combined with PSD502.Investigational
QuazepamThe serum concentration of Ropivacaine can be increased when it is combined with Quazepam.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Quetiapine.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Ropivacaine.Approved, Investigational
QuinidineThe metabolism of Ropivacaine can be decreased when combined with Quinidine.Approved
QuinineThe metabolism of Ropivacaine can be decreased when combined with Quinine.Approved
RacloprideThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Ramelteon.Approved, Investigational
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Ropivacaine.Approved
RanolazineThe metabolism of Ropivacaine can be decreased when combined with Ranolazine.Approved, Investigational
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Ropivacaine.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Remifentanil.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Remoxipride.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Ropivacaine.Approved
RifabutinThe metabolism of Ropivacaine can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Ropivacaine can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Ropivacaine can be increased when combined with Rifapentine.Approved
RiociguatThe risk or severity of adverse effects can be increased when Riociguat is combined with Ropivacaine.Approved
RisperidoneRopivacaine may increase the hypotensive activities of Risperidone.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Ritanserin.Investigational
RitonavirThe metabolism of Ropivacaine can be decreased when combined with Ritonavir.Approved, Investigational
RolapitantThe metabolism of Ropivacaine can be decreased when combined with Rolapitant.Approved
RomifidineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Romifidine.Vet Approved
RopiniroleRopivacaine may increase the sedative activities of Ropinirole.Approved, Investigational
RotigotineRopivacaine may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Ropivacaine.Approved
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Ropivacaine is combined with S-Ethylisothiourea.Experimental
SacubitrilThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Sacubitril.Approved
Sage 547The risk or severity of adverse effects can be increased when Ropivacaine is combined with Sage 547.Investigational
SaquinavirThe metabolism of Ropivacaine can be decreased when combined with Saquinavir.Approved, Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Scopolamine.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Secobarbital.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Selegiline.Approved, Investigational, Vet Approved
SertindoleThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Sertindole.Approved, Withdrawn
SertralineThe metabolism of Ropivacaine can be decreased when combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Sevoflurane.Approved, Vet Approved
SildenafilThe metabolism of Ropivacaine can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Ropivacaine can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Ropivacaine can be increased when it is combined with Simeprevir.Approved
Sodium NitriteThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Sodium Nitrite.Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Ropivacaine.Approved
SorafenibThe metabolism of Ropivacaine can be decreased when combined with Sorafenib.Approved, Investigational
SotalolThe risk or severity of adverse effects can be increased when Sotalol is combined with Ropivacaine.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Ropivacaine.Approved
St. John's WortThe serum concentration of Ropivacaine can be decreased when it is combined with St. John's Wort.Nutraceutical
StiripentolThe serum concentration of Ropivacaine can be increased when it is combined with Stiripentol.Approved
StreptokinaseThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Streptokinase.Approved
SufentanilThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Sufentanil.Approved, Investigational
SulfisoxazoleThe metabolism of Ropivacaine can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulpirideThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Sulpiride.Approved
SuvorexantRopivacaine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TamsulosinThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Tamsulosin.Approved, Investigational
TandospironeThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Ropivacaine.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Tasimelteon.Approved
Technetium Tc-99m tilmanoceptRopivacaine may decrease effectiveness of Technetium Tc-99m tilmanocept as a diagnostic agent.Approved
TelaprevirThe metabolism of Ropivacaine can be decreased when combined with Telaprevir.Approved
TelithromycinThe metabolism of Ropivacaine can be decreased when combined with Telithromycin.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Ropivacaine.Approved, Investigational
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Ropivacaine.Approved
TenofovirThe metabolism of Ropivacaine can be decreased when combined with Tenofovir.Approved, Investigational
TerazosinThe risk or severity of adverse effects can be increased when Terazosin is combined with Ropivacaine.Approved
TerbinafineThe metabolism of Ropivacaine can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TeriflunomideThe serum concentration of Ropivacaine can be decreased when it is combined with Teriflunomide.Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Tetrabenazine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Tetracaine.Approved, Vet Approved
TetrodotoxinThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Tetrodotoxin.Investigational
ThalidomideRopivacaine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
TheophyllineThe metabolism of Ropivacaine can be decreased when combined with Theophylline.Approved
ThiamylalThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Thiamylal.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Thiopental.Approved, Vet Approved
ThioridazineThe metabolism of Ropivacaine can be decreased when combined with Thioridazine.Approved
ThiotepaThe metabolism of Ropivacaine can be decreased when combined with Thiotepa.Approved
ThiothixeneThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Thiothixene.Approved
TiagabineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Tiagabine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Tiapride.Investigational
TiclopidineThe metabolism of Ropivacaine can be decreased when combined with Ticlopidine.Approved
TiletamineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Tiletamine.Vet Approved
TimololThe risk or severity of adverse effects can be increased when Timolol is combined with Ropivacaine.Approved
TipranavirThe metabolism of Ropivacaine can be decreased when combined with Tipranavir.Approved, Investigational
TizanidineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Tizanidine.Approved
TocilizumabThe serum concentration of Ropivacaine can be decreased when it is combined with Tocilizumab.Approved
TolazolineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Tolazoline.Approved, Vet Approved
TolcaponeThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Tolcapone.Approved, Withdrawn
TopiramateThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Topiramate.Approved
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Ropivacaine.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Ropivacaine.Approved, Investigational
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Ropivacaine.Approved
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Trans-2-Phenylcyclopropylamine.Experimental
TranylcypromineThe metabolism of Ropivacaine can be decreased when combined with Tranylcypromine.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Trazodone.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Tretinoin.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Ropivacaine.Approved
TriazolamThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Triazolam.Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Trifluoperazine.Approved
TriflupromazineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Triflupromazine.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Triprolidine.Approved
Uc1010The risk or severity of adverse effects can be increased when Ropivacaine is combined with Uc1010.Investigational
Valproic AcidThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Valproic Acid.Approved, Investigational
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Ropivacaine.Approved, Investigational
VemurafenibThe serum concentration of Ropivacaine can be increased when it is combined with Vemurafenib.Approved
VenlafaxineThe metabolism of Ropivacaine can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Ropivacaine can be decreased when combined with Verapamil.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Vigabatrin.Approved
VoriconazoleThe metabolism of Ropivacaine can be decreased when combined with Voriconazole.Approved, Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Vortioxetine.Approved
XylazineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Xylazine.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Zaleplon.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Zimelidine.Withdrawn
ZiprasidoneThe metabolism of Ropivacaine can be decreased when combined with Ziprasidone.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Zolazepam.Vet Approved
ZolpidemRopivacaine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Zopiclone.Approved
ZotepineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Zotepine.Approved
ZuclopenthixolThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Zuclopenthixol.Approved, Investigational
Food InteractionsNot Available
References
Synthesis Reference

Peter Jaksch, “Process for the preparation of ropivacaine hydrochloride monohydrate.” U.S. Patent US5959112, issued February, 1970.

US5959112
General References
  1. Weinberg G, Ripper R, Feinstein DL, Hoffman W: Lipid emulsion infusion rescues dogs from bupivacaine-induced cardiac toxicity. Reg Anesth Pain Med. 2003 May-Jun;28(3):198-202. [PubMed:12772136 ]
  2. Picard J, Meek T: Lipid emulsion to treat overdose of local anaesthetic: the gift of the glob. Anaesthesia. 2006 Feb;61(2):107-9. [PubMed:16430560 ]
  3. Rosenblatt MA, Abel M, Fischer GW, Itzkovich CJ, Eisenkraft JB: Successful use of a 20% lipid emulsion to resuscitate a patient after a presumed bupivacaine-related cardiac arrest. Anesthesiology. 2006 Jul;105(1):217-8. [PubMed:16810015 ]
External Links
ATC CodesN01BB09
AHFS Codes
  • 72:00.00
PDB EntriesNot Available
FDA labelDownload (274 KB)
MSDSDownload (57 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9705
Blood Brain Barrier+0.9377
Caco-2 permeable+0.5912
P-glycoprotein substrateSubstrate0.8037
P-glycoprotein inhibitor IInhibitor0.8768
P-glycoprotein inhibitor IINon-inhibitor0.6339
Renal organic cation transporterNon-inhibitor0.6611
CYP450 2C9 substrateNon-substrate0.819
CYP450 2D6 substrateSubstrate0.8919
CYP450 3A4 substrateSubstrate0.723
CYP450 1A2 substrateNon-inhibitor0.5499
CYP450 2C9 inhibitorNon-inhibitor0.9246
CYP450 2D6 inhibitorInhibitor0.8821
CYP450 2C19 inhibitorNon-inhibitor0.8773
CYP450 3A4 inhibitorNon-inhibitor0.5902
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.6116
Ames testNon AMES toxic0.8507
CarcinogenicityNon-carcinogens0.8763
BiodegradationNot ready biodegradable0.9783
Rat acute toxicity2.2964 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8009
hERG inhibition (predictor II)Inhibitor0.8438
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • App pharmaceuticals llc
Packagers
Dosage forms
FormRouteStrength
Injection, solutionEpidural; Infiltration2 mg/mL
SolutionEpidural10 mg
SolutionEpidural; Infiltration2 mg
SolutionEpidural5 mg
LiquidParenteral7.5 mg
Injection, solutionEpidural10 mg/mL
Injection, solutionEpidural; Infiltration; Perineural2 mg/mL
Injection, solutionEpidural; Infiltration; Perineural5 mg/mL
Injection, solutionEpidural; Perineural7.5 mg/mL
Injection, solutionParenteral10 mg/mL
Injection, solutionParenteral5 mg/mL
SolutionEpidural; Infiltration10 mg
SolutionEpidural; Infiltration5 mg
SolutionEpidural7.5 mg
SolutionInfiltration2 mg
Prices
Unit descriptionCostUnit
Ropivacaine hcl-ns 0.5%1.84USD ml
Ropivacaine hcl 0.2% on-q pump0.99USD ml
Naropin 10 mg/ml ampule0.97USD ml
Ropivacaine hcl-ns 0.3%0.9USD ml
Ropivacaine-ns 0.1% on-q pump0.71USD ml
Naropin 7.5 mg/ml ampule0.62USD ml
Naropin 5 mg/ml vial0.58USD ml
Ropivacaine hcl-ns 0.15%0.51USD ml
Ropivacaine hcl-ns 0.125%0.48USD ml
Naropin 5 mg/ml ampule0.46USD ml
Naropin 2 mg/ml ampule0.44USD ml
Ropivacaine hcl-ns 0.1%0.39USD ml
Ropivacaine hcl-ns 0.25%0.34USD ml
Ropivacaine hcl-ns 0.2%0.29USD ml
Naropin 2 mg/ml infusion btl0.23USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA1337549 No1995-11-142012-11-14Canada
CA2165446 No2005-07-052014-05-26Canada
US4870086 No1993-09-242010-09-24Us
US5670524 No1994-05-262014-05-26Us
US7828787 No2005-10-182025-10-18Us
US7857802 No2006-11-282026-11-28Us
US8118802 No2003-05-182023-05-18Us
US8162915 No2004-05-232024-05-23Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
water solubility57.6 mg/LNot Available
logP2.90HANSCH,C ET AL. (1995)
pKa8.07Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.253 mg/mLALOGPS
logP2.91ALOGPS
logP4.07ChemAxon
logS-3ALOGPS
pKa (Strongest Acidic)13.62ChemAxon
pKa (Strongest Basic)7.82ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area32.34 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity85.59 m3·mol-1ChemAxon
Polarizability32.67 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as alpha amino acid amides. These are amide derivatives of alpha amino acids.
KingdomOrganic compounds
Super ClassOrganic acids and derivatives
ClassCarboxylic acids and derivatives
Sub ClassAmino acids, peptides, and analogues
Direct ParentAlpha amino acid amides
Alternative Parents
Substituents
  • Alpha-amino acid amide
  • N-arylamide
  • Piperidinecarboxylic acid
  • Piperidinecarboxamide
  • 2-piperidinecarboxamide
  • Benzenoid
  • Piperidine
  • Monocyclic benzene moiety
  • Tertiary aliphatic amine
  • Tertiary amine
  • Secondary carboxylic acid amide
  • Carboxamide group
  • Azacycle
  • Organoheterocyclic compound
  • Carboxylic acid amide
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Voltage-gated sodium channel activity
Specific Function:
Tetrodotoxin-resistant channel that mediates the voltage-dependent sodium ion permeability of excitable membranes. Assuming opened or closed conformations in response to the voltage difference across the membrane, the protein forms a sodium-selective channel through which sodium ions may pass in accordance with their electrochemical gradient. Plays a role in neuropathic pain mechanisms.
Gene Name:
SCN10A
Uniprot ID:
Q9Y5Y9
Molecular Weight:
220623.605 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Liu BG, Zhuang XL, Li ST, Xu GH: The effects of ropivacaine on sodium currents in dorsal horn neurons of neonatal rats. Anesth Analg. 2000 May;90(5):1034-8. [PubMed:10781449 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Arlander E, Ekstrom G, Alm C, Carrillo JA, Bielenstein M, Bottiger Y, Bertilsson L, Gustafsson LL: Metabolism of ropivacaine in humans is mediated by CYP1A2 and to a minor extent by CYP3A4: an interaction study with fluvoxamine and ketoconazole as in vivo inhibitors. Clin Pharmacol Ther. 1998 Nov;64(5):484-91. [PubMed:9834040 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Acts as a 1,4-cineole 2-exo-monooxygenase.
Gene Name:
CYP2B6
Uniprot ID:
P20813
Molecular Weight:
56277.81 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on December 03, 2016 02:44